Strides Pharma, also known as Strides Pharma Science Limited, is a major Indian pharmaceutical company headquartered in Bangalore.
Strides Pharma Overview
| Feature | Description |
|---|---|
| Focus | Develops and manufactures IP-led niche finished dosage formulations; leading global manufacturer of soft gelatin capsules |
| Areas of Expertise | Branded generics, global marketing and distribution, R&D in niche therapeutic areas |
| Strengths | World-class manufacturing facilities, innovative R&D hub, robust commercial platform, proven track record |
| Additional Information | Publicly traded company (NSE & BSE), 6,000+ employees, focus on partnerships |
Strides Pharma Products
| Category | Description | Examples |
|---|---|---|
| Branded Generics: | Affordable versions of established medications | Albuterol, Amoxicillin, Metformin |
| Specialty Products: | Niche formulations with unique delivery systems or targeting specific conditions | Modified-release tablets, Softgel capsules, Topical ointments |
| Over-the-Counter (OTC): | Non-prescription medications for common ailments | Cough syrups, Pain relievers, Digestive aids |
| Consumer Healthcare: | Wellness products and nutritional supplements | Vitamins, Minerals, Herbal remedies |
Strides Pharma Awards and Recognition
| Award/Recognition | Year | Category | Description |
|---|---|---|---|
| LACP Platinum Award | 2009 | Annual Report Competition | Strides’ 2009 Annual Report won “Platinum” in the Pharma US$100m to US$1b category, lauded for its clarity, creativity, and information accessibility. |
| Frost & Sullivan Asia Pacific Generics Drug Manufacturing Leadership Award | 2012 | Pharmaceutical Manufacturing | Recognized for its innovative manufacturing practices, operational excellence, and commitment to quality. |
| CII National Award for Excellence in Energy Management | 2015 | Energy Efficiency | Applauded for its efforts in implementing energy-saving measures and promoting sustainable practices. |
| AstraZeneca Supplier Excellence Award | 2016 | Manufacturing Excellence | Awarded by AstraZeneca for consistently exceeding expectations in quality, delivery, and service. |
| CIPA Excellence Awards – Finalist for Quality Excellence Award | 2018 | Pharmaceutical Quality | Shortlisted for its commitment to maintaining the highest quality standards in manufacturing and product development. |
| Great Place to Work® Certification (India) | 2022 & 2023 | Employer Recognition | Recognized for fostering a positive and engaging work environment for its employees. |
Strides Pharma Fundamentals
| Metric | Value |
|---|---|
| Market Capitalization | ₹5,862.90 Crore |
| Revenue (TTM) | ₹3,940.93 Crore |
| EBITDA (TTM) | ₹605.42 Crore |
| EPS (TTM) | ₹-4.39 |
| P/E Ratio | – |
| P/B Ratio | 3.11 |
| Dividend Yield | 0.00% |
| Debt/Equity Ratio | 0.80 |
| Book Value | ₹189.94 |
| Face Value | ₹2 |
| ROE | -2.31% |
| Debt | ₹3,169.32 Crore |
Strides Pharma Revenue and Net Profit
| Period | Revenue | Net Profit/Loss | Year-over-Year (YoY) Revenue Change | YoY Net Profit/Loss Change |
|---|---|---|---|---|
| Q2 FY24 (Sep 2023) | 999.43 | -149.34 | 11.41% | -675.3% |
| Q1 FY24 (Jun 2023) | 901.80 | -24.02 | 7.46% | -1462.0% |
| FY23 (Mar 2023) | 3,940.93 | -202.64 | 5.05% | -460.21% |
| FY22 (Mar 2022) | 3,752.82 | 268.44 | 13.49% | 36.39% |
| FY21 (Mar 2021) | 3,299.57 | 36.39 | 23.44% | -58.05% |
Strides Pharma Shareholding Patterns
| Category | Shareholding |
|---|---|
| Promoters: | 27.79 |
| Foreign Public Shareholders: | 0.21 |
| Domestic Public Shareholders: | 72.00 |
| – Individual Shareholders: | 41.82 |
| – Mutual Funds: | 16.28 |
| – Financial Institutions: | 5.97 |
| – Others: | 7.93 |
Strides Pharma Share Price Target for 2025, 2026, 2027, 2028, 2029
| Year | Target Price |
|---|---|
| 2025 | ₹1000 |
| 2026 | ₹1500 |
| 2027 | ₹2000 |
| 2028 | ₹2500 |
| 2029 | ₹3000 |
Strides Pharma Share Price Target for 2025
Strides Pharma Share Price Target for 2025 is 1000.
Strides Pharma Share Price Target for 2026
Strides Pharma Share Price Target for 2026 is 1500.
Strides Pharma Share Price Target for 2027
Strides Pharma Share Price Target for 2027 is 2000.
Strides Pharma Share Price Target for 2028
Strides Pharma Share Price Target for 2028 is 2500.
Strides Pharma Share Price Target for 2029
Strides Pharma Share Price Target for 2029 is 3000.
Read more:
Strides Pharma Dividend History
| Date | Dividend (₹ per share) | Split Adjusted Dividend | YoY Change |
|---|---|---|---|
| May 25, 2023 | 1.50 | 1.50 | -50.00% |
| July 19, 2019 | 3.00 | 3.75 | -56.00% |
| September 12, 2018 | 2.00 | 2.50 | N/A |
| September 07, 2017 | 4.50 | 5.63 | N/A |
| August 22, 2019 | 12.00 | 15.00 | N/A |
Future Outlook of Strides Pharma
Positives:
- Strong business model: Strides Pharma excels in developing and manufacturing complex niche finished dosage formulations, giving them a competitive edge in specific therapeutic areas.
- Global presence: They have a diversified geographical footprint with a strong presence in regulated markets and emerging economies, offering growth opportunities.
- Focus on R&D:Â Their investments in research and development can lead to new product pipelines and revenue streams.
- Debt reduction plan:Â Their commitment to reducing debt will improve their financial health and attract investors.
- Recent demerger:Â The spin-off of their CDMO and soft gelatin businesses could streamline operations and improve profitability.
Risks Associated With Investing in Strides Pharma
| Category | Risk | Description |
|---|---|---|
| Financial | Profitability Concerns: | Recent losses raise questions about financial sustainability and future profitability. |
| High Debt Level: | Debt-to-equity ratio of 0.80 indicates potential financial strain and limited room for maneuver. | |
| Dependence on a Few Key Markets: | Over-reliance on specific markets like the US exposes them to regional economic fluctuations. | |
| Industry | Competitive Landscape: | The pharmaceutical industry is highly competitive, with established players and new entrants vying for market share. |
| Stringent Regulations: | Delays in product approvals due to regulations can impact revenue and timelines. | |
| Patent Expiry Risks: | Expiry of key patents for existing products can lead to loss of market share and revenue. | |
| Operational | Supply Chain Disruptions: | Geopolitical tensions and unexpected events can disrupt their supply chains and impact production. |
| R&D Challenges: | Dependence on successful R&D pipeline for future growth, with potential for delays or failures. | |
| Integration Risks: | Recent demerger of business units might bring unforeseen integration challenges. |
Strides Pharma Competitors
| Competitor | Focus | Strengths |
|---|---|---|
| Sun Pharma Industries Ltd. | Generic & branded drugs | Extensive product portfolio, strong domestic presence, robust R&D. |
| Cipla Ltd. | Generic & branded drugs | Global reach, strong presence in Africa, focus on niche segments. |
| Dr. Reddy’s Laboratories Ltd. | Generic & branded drugs, APIs | Strong R&D capabilities, vertically integrated operations, focus on complex generics. |
| Zydus Cadila Healthcare Ltd. | Generic & branded drugs, research & development | Broad product portfolio, affordable healthcare initiatives, diversifying into R&D. |
| Glenmark Pharmaceuticals Ltd. | Generics & branded drugs, innovative therapies | Growing international presence, focus on respiratory & dermatology. |
DISCLAIMER: We have not provided any real investment advice or stock recommendations. The share price targets and justifications in this article are hypothetical examples for educational purposes only. Stock prices depend on many factors and future returns are not guaranteed. Readers should do their own research before investing. Or consult a registered financial advisor for guidance. We do not guarantee any stock performance or returns. Investing in stocks involves risks.
